How much help does a vaccine-induced T-cell response need?
作者信息
Weber J S, Mulé J J
机构信息
Department of Medicine, Keck/University of Southern California School of Medicine and Norris Comprehensive Cancer Center, Los Angeles, California, USA.
出版信息
J Clin Invest. 2001 Mar;107(5):553-4. doi: 10.1172/JCI12403.
Abstract
摘要
相似文献
1
How much help does a vaccine-induced T-cell response need?
J Clin Invest. 2001 Mar;107(5):553-4. doi: 10.1172/JCI12403.
2
DC-based cancer vaccines: lessons from clinical trials.
Cytotherapy. 2004;6(2):122-7. doi: 10.1080/14653240410005267.
3
[Peptide-based vaccine therapy for cancer patients].
Nihon Rinsho. 2005 Apr;63 Suppl 4:602-7.
4
DCs in lymphoma--biology and therapeutic aspects.
Cytotherapy. 2004;6(2):138-47. doi: 10.1080/14653240410006095.
5
Generation of dendritic cell-based vaccines for cancer therapy.
Br J Cancer. 2002 May 20;86(10):1529-33. doi: 10.1038/sj.bjc.6600316.
6
Immunotherapy of surgical malignancies.
Curr Probl Surg. 2004 Jan;41(1):15-132. doi: 10.1016/S0011384003001321.
7
Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
Expert Opin Biol Ther. 2010 Nov;10(11):1539-53. doi: 10.1517/14712598.2010.526105.
8
DC therapy for metastatic melanoma.
Cytotherapy. 2004;6(2):148-53. doi: 10.1080/14653240410005627.
9
T-cell epitope peptide vaccines.
Expert Rev Vaccines. 2004 Oct;3(5):563-75. doi: 10.1586/14760584.3.5.563.
10
Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Cell Res. 2006 Mar;16(3):241-59. doi: 10.1038/sj.cr.7310032.
引用本文的文献
1
Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.
J Clin Immunol. 2004 Jul;24(4):449-61. doi: 10.1023/B:JOCI.0000029117.10791.98.
本文引用的文献
1
Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis-inducing agents.
Cancer Res. 2001 Jan 1;61(1):228-36.
2
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.
J Clin Invest. 2001 Feb;107(4):477-84. doi: 10.1172/JCI11752.
3
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
J Clin Oncol. 2001 Jan 1;19(1):145-56. doi: 10.1200/JCO.2001.19.1.145.
4
Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine.
J Immunother. 2000 Jul-Aug;23(4):401-4. doi: 10.1097/00002371-200007000-00002.
5
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
Cancer Res. 2000 Jun 15;60(12):3239-46.
6
Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
J Immunol. 2000 May 1;164(9):4797-803. doi: 10.4049/jimmunol.164.9.4797.
7
Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes.
J Clin Invest. 2000 Mar;105(6):R9-R14. doi: 10.1172/JCI9051.
8
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
J Immunol. 2000 Apr 1;164(7):3535-42. doi: 10.4049/jimmunol.164.7.3535.
9
Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.
J Exp Med. 2000 Feb 21;191(4):625-30. doi: 10.1084/jem.191.4.625.
10
Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses.
J Immunol. 2000 Feb 1;164(3):1625-33. doi: 10.4049/jimmunol.164.3.1625.
Zotero 插件